The General
New Member
United Cannabis Corp. had filed for a patent on its cannabinoids with the U.S. Patent and Trademark Office, with the hopes of expanding its medical marijuana capabilities. The Denver-based company wants to offer its cannabinoids in pill form for the treatment of various ailments, including post traumatic stress disorder and neuropathy, said Chad Ruby, COO of United Cannabis.
United Cannabis (OTCBB: CNAB) uses a proprietary strain of marijuana, Prana Bio Nutrient Medicinals, to treat very ill patients, Ruby said. In preclinical and clinical studies, researchers from United Cannabis developed medications based on delivering cannabinoids at specific ratios and timing that helps the body reestablish homeostasis, or the state in which variables in the body are stable and relatively constant.
"We've been able to exploit this effect and have developed treatment programs and protocols to treat a wide variety of disorders," said Tony Verzura, chief technology officer for United Cannabis. In the future, the company hopes to expand on these findings to try and reverse the effects of the certain disorder.
"Our focus is not on the treatment of symptoms of disease, but rather on reversing the underlying pathology that drives and contributes to specific disorders. These patents stem from that unique approach and the success we have seen for patients using our Prana products and ACT Now Program," Verzura said. The ACT Now Program refers to United Cannabis' Advanced Cannabinoid Therapy software, a cloud-based electronic health record software used by physicians to handle scheduling, billing and other necessary information. The software is compliant with the Health Insurance Portability and Accountability Act and allows patients access to all their health records, including cannabinoid-based treatment programs using Prana Bio Nutrient Medicinals.
United Cannabis will take its product through clinical trial steps during the patenting process. This includes phase 1 safety trials and phase 2 and 3 efficacy trials, Verzura said. United Cannabis this week also announced that it has signed an exclusive, 10-year agreement with a Dutch company to distribute its products. Amsterdam-based DNA Genetics has researched and developed hundreds of cannabis strains, according to United Cannabis. Under the agreement, United Cannabis will serve as the distributor for DNA Genetics in Colorado and will have first right of refusal in all states where DNA Genetics become licensed.
The companies will work together to develop a regional breeding program to develop plants in each of the geographic areas where United Cannabis or its affiliates grow, refine or dispense pot. This will allow both companies to comply with regulations that prohibit the sale or transfer of any cannabis plant materials between markets, United Cannabis said.
News Moderator - The General @ 420 MAGAZINE ®
Source: Bizjournals.com
Author: Molly Armbrister
Contact: Contact Us
Website: Denver company applies for pot patent for treatments - Denver Business Journal
United Cannabis (OTCBB: CNAB) uses a proprietary strain of marijuana, Prana Bio Nutrient Medicinals, to treat very ill patients, Ruby said. In preclinical and clinical studies, researchers from United Cannabis developed medications based on delivering cannabinoids at specific ratios and timing that helps the body reestablish homeostasis, or the state in which variables in the body are stable and relatively constant.
"We've been able to exploit this effect and have developed treatment programs and protocols to treat a wide variety of disorders," said Tony Verzura, chief technology officer for United Cannabis. In the future, the company hopes to expand on these findings to try and reverse the effects of the certain disorder.
"Our focus is not on the treatment of symptoms of disease, but rather on reversing the underlying pathology that drives and contributes to specific disorders. These patents stem from that unique approach and the success we have seen for patients using our Prana products and ACT Now Program," Verzura said. The ACT Now Program refers to United Cannabis' Advanced Cannabinoid Therapy software, a cloud-based electronic health record software used by physicians to handle scheduling, billing and other necessary information. The software is compliant with the Health Insurance Portability and Accountability Act and allows patients access to all their health records, including cannabinoid-based treatment programs using Prana Bio Nutrient Medicinals.
United Cannabis will take its product through clinical trial steps during the patenting process. This includes phase 1 safety trials and phase 2 and 3 efficacy trials, Verzura said. United Cannabis this week also announced that it has signed an exclusive, 10-year agreement with a Dutch company to distribute its products. Amsterdam-based DNA Genetics has researched and developed hundreds of cannabis strains, according to United Cannabis. Under the agreement, United Cannabis will serve as the distributor for DNA Genetics in Colorado and will have first right of refusal in all states where DNA Genetics become licensed.
The companies will work together to develop a regional breeding program to develop plants in each of the geographic areas where United Cannabis or its affiliates grow, refine or dispense pot. This will allow both companies to comply with regulations that prohibit the sale or transfer of any cannabis plant materials between markets, United Cannabis said.
News Moderator - The General @ 420 MAGAZINE ®
Source: Bizjournals.com
Author: Molly Armbrister
Contact: Contact Us
Website: Denver company applies for pot patent for treatments - Denver Business Journal
